Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Risk for severe irAEs noted with sequential PD-1/PD-L1 blockade and osimertinib

Pills and water (symbolic image with model)

Patients with advanced EGFR mutation-positive non-small-cell lung cancer who receive osimertinib directly after agents targeting PD-1 or PD-L1 may be at increased risk for developing severe immune-related adverse events, suggests a chart review.

Sex disparity identified for hyperprogressive disease after immunotherapy

Male & female outlines_chalk

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

Immunotherapy-based regimens show promise in non-clear-cell RCC

Human kidney cross section

Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.

Latest headlines

22-03-2019 | Castration-sensitive prostate cancer | News

Docetaxel add-on improves outcomes in high-risk localized prostate cancer

Adding docetaxel chemotherapy to standard long-term androgen suppression plus radiotherapy significantly improves survival in patients with high-risk nonmetastatic prostate cancer, show data from the NRG Oncology RTOG 0521 study.

21-03-2019 | Atezolizumab | News | Article

Second-line atezoliumab feasible for advanced urothelial carcinoma with comorbidity

Results from the SAUL study add support for the use of atezolizumab in patients with advanced urothelial or nonurothelial carcinoma of the urinary tract, including those with autoimmune disease and other comorbidities.

19-03-2019 | Castration-resistant prostate cancer | News

AR-V7 status predicts abiraterone, enzalutamide response in mCRPC

Men positive for androgen receptor splice variant 7 in circulating tumor cells derive little benefit from abiraterone or enzalutamide in the treatment of metastatic castration-resistant prostate cancer, US researchers report.

In depth

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

28-01-2019 | Immunotherapy | At a glance | Article

Gut microbiota and immunotherapy response: A round-up of the trials

A round-up of the key studies – all published in Science – that have investigated the association between the gut microbiome and response to immune checkpoint inhibitors.

image credits